Non-ASH Meetings

Non-ASH Meetings

On-site interview with presenters at meetings and summits in the hematology/oncology arena

Kathi Mooney: Impact of Remote Monitoring on Patients with Cancer During the COVID-19 Pandemic

Remote monitoring and treatment of cancer and treatment-related symptoms during the COVID-19 pandemic was associated with significant reductions in symptom burden and improvements in...

Ann LaCasce: PET Adapted Therapy Allows Omission of Radiation Therapy in Classic Hodgkin Lymphoma

Ann S. LaCasce, MD, shares data from the Alliance for Clinical Trials in Oncology’s CALGB-50801 trial, which evaluated a PET-adapted approach to cHL therapy.

Paolo Ghia: Ibrutinib Plus Venetoclax Produces Deep Responses in Patients with CLL/SLL

Here, Paolo Ghia, MD, PhD, of Vita-Salute San Raffaele University in Milan, Italy, discusses recent findings from the phase II CAPTIVATE study evaluating fixed-duration...

Vincent Wagner and Ellen Marcus: Use of the Khorana Score to Predict VTE

Vincent Wagner, MD, and Ellen Marcus, BA, discuss the Khorana score's role in assessing risk of venous thromboembolism (VTE) in patients with gynecological cancers.

Curtis Andrew Lachowiez: Ivosidenib + Venetoclax and Azacitidine in IDH-Mutated Myeloid Malignancies

In this video, Curtis Andrew Lachowiez, MD, discusses interim results from a small study of patients with IDH1-mutated myeloid malignancies who were treated with ivosidenib plus...

Saad Usmani: Updated Results from the CARTITUDE-1 Trial in Patients with Heavily Pretreated Myeloma

In this video, Saad Z. Usmani, MBA, MD, discusses updated results from the CARTITUDE-1 trial evaluating ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

Constantine Tam: Comparing Zanubrutinib With Ibrutinib in Waldenström Macroglobulinemia

Treatment with zanubrutinib resulted in a higher combined complete response and very good partial response rate than therapy with ibrutinib in patients with Waldenström...

Meletios Dimopoulos: Weekly SVd Improved PFS in Relapsed/Refractory Myeloma

Once weekly combination treatment with selinexor, bortezomib, and dexamethasone led to an approximately 4-month improvement in progression-free survival compared with bortezomib plus dexamethasone. Meletios...

Shaji Kumar: Comparing KRd With VRd in Newly Diagnosed Myeloma

Initial treatment with carfilzomib, lenalidomide, and dexamethasone was not associated with greater improvements in progression-free survival compared with bortezomib, lenalidomide, and dexamethasone. Shaji Kumar,...

Ajay Nooka: Belantamab Mafodotin in Relapsed/Refractory Myeloma

Ajay K. Nooka, MD, shares safety and efficacy data from the phase II DREAMM-6 trial.
Advertisement

Current Issue

September 2021 Volume 7 Issue 11

This issue discusses fertility preservation for young patients with cancer, reviews treatment options for primary immune thrombocytopenia, and more.

Block title